Document ID: chunk:federal_register_of_legislation:F2016L00560:reg:9:p2
Version: federal_register_of_legislation:F2016L00560
Segment Type: reg
Provision Reference: reg 9 (pt 2/6)
Character Range: 7765–11162

of hydrocephalus, within the three months before the clinical onset of secondary parkinsonism;
Note: hydrocephalus is defined in the Schedule 1 - Dictionary.
            (e)          having a cerebrovascular accident, excluding transient ischaemic attack, within the five years before the clinical onset of secondary parkinsonism;
            (f)           having a disease from the specified list of diseases involving the cerebral vessels, in the presence of neuroimaging findings of brain stem or cerebral white matter lesions, haemorrhage or infarction, at the time of the clinical onset of secondary parkinsonism;
Note: specified list of diseases involving the cerebral vessels is defined in the Schedule 1 - Dictionary.
            (g)          having a subarachnoid haemorrhage within the three months before the clinical onset of secondary parkinsonism;
            (h)          having an acquired cerebrovascular malformation or dural arteriovenous fistula at the time of the clinical onset of secondary parkinsonism;
            (i)            having an hypoxic cerebral insult within the two years before the clinical onset of secondary parkinsonism;
Note: hypoxic cerebral insult is defined in the Schedule 1 - Dictionary.
            (j)            having influenza within the three months before the clinical onset of secondary parkinsonism;
            (k)          having encephalitis within the three months before the clinical onset of secondary parkinsonism;
Note: encephalitis is defined in the Schedule 1 - Dictionary.
            (l)            being infected with the human immunodeficiency virus before the clinical onset of secondary parkinsonism;
            (m)        having neurosyphilis at the time of the clinical onset of secondary parkinsonism;
Note: neurosyphilis is defined in the Schedule 1 - Dictionary.
            (n)          having neurocysticercosis at the time of the clinical onset of secondary parkinsonism;
            (o)          inhaling carbon disulphide vapour in an enclosed space, or having cutaneous contact with carbon disulphide, for a cumulative period of at least 500 hours, within the ten years before the clinical onset of secondary parkinsonism;
            (p)          inhaling trichloroethylene vapour in an enclosed space, or having cutaneous contact with trichloroethylene, for a cumulative period of at least 2 000 hours, within the 20 years before the clinical onset of secondary parkinsonism;
            (q)          inhaling or ingesting methanol or ethylene glycol, and having clinical, haematological or biochemical evidence of methanol or ethylene glycol intoxication, within the three months before the clinical onset of secondary parkinsonism;
            (r)           being exposed to manganese as specified for a cumulative period of at least 250 hours, within the ten years before the clinical onset of secondary parkinsonism;
Note: being exposed to manganese as specified is defined in the Schedule 1 - Dictionary.
            (s)           having clinical or biochemical evidence of manganese intoxication while receiving total parenteral nutrition or maintenance haemodialysis, at the time of the clinical onset of secondary parkinsonism;
Note: total parenteral nutrition is defined in the Schedule 1 - Dictionary.
            (t)            inhaling, ingesting or having cutaneous contact with cyanide, and having